We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

220 hedge funds and large institutions have $2.44B invested in Immunomedics Inc in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 65 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $28.6M | Put options by funds: $15.9M

25% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 65

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

10% less funds holding

Funds holding: 245220 (-25)

33% less capital invested

Capital invested by funds: $3.65B → $2.44B (-$1.22B)

39% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 54

Holders
220
Holders Change
-25
Holders Change %
-10.2%
% of All Funds
4.85%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.15%
New
33
Increased
81
Reduced
65
Closed
54
Calls
$28.6M
Puts
$15.9M
Net Calls
+$12.7M
Net Calls Change
-$36.3M
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$330M
Vanguard Group
2
Vanguard Group
Pennsylvania
$227M +$9.52M +566,009 +3%
BlackRock
3
BlackRock
New York
$213M +$18.2M +1,081,297 +7%
BC
4
Boxer Capital
California
$114M
State Street
5
State Street
Massachusetts
$95.4M +$4.94M +293,759 +4%
PAI
6
Palo Alto Investors
California
$71.3M -$10.6M -632,449 -11%
ACH
7
ArrowMark Colorado Holdings
Colorado
$70.7M -$2.46M -146,080 -3%
Ameriprise
8
Ameriprise
Minnesota
$70M +$14.3M +852,321 +20%
Jennison Associates
9
Jennison Associates
New York
$67.7M +$33.6M +1,997,717 +66%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$66.4M -$15.1M -899,168 -15%
RM
11
RP Management
New York
$59M
Fidelity Investments
12
Fidelity Investments
Massachusetts
$57M -$6.48M -385,366 -8%
DM
13
Deerfield Management
New York
$55.4M +$40.1M +2,384,846 +138%
Victory Capital Management
14
Victory Capital Management
Texas
$49M +$33.9M +2,016,570 +125%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$47.2M +$58.9M +3,498,974 New
Alkeon Capital Management
16
Alkeon Capital Management
New York
$42M +$4.21M +250,000 +9%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$37.4M +$3.91M +232,241 +9%
Citadel Advisors
18
Citadel Advisors
Florida
$37.3M +$42.5M +2,525,137 +1,041%
Fiera Capital (Canada)
19
Fiera Capital (Canada)
Quebec, Canada
$37M -$1.78M -105,669 -4%
American Century Companies
20
American Century Companies
Missouri
$35.6M -$6.15M -365,715 -12%
Janus Henderson Group
21
Janus Henderson Group
United Kingdom
$35.1M -$18.5M -1,097,094 -30%
Northern Trust
22
Northern Trust
Illinois
$30.8M +$2.72M +161,841 +8%
Wells Fargo
23
Wells Fargo
California
$28.4M -$3.22M -191,441 -8%
FLAM
24
First Light Asset Management
Minnesota
$27.2M +$13M +771,860 +62%
WP
25
Woodline Partners
California
$26.2M +$23M +1,366,256 +238%

IMMU Hedge Fund Activity: Q1 2020 in Review

220 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2020, worth a combined $2.44B — down 33% from $3.65B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of IMMU and 33 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 81 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $58.9M. The largest seller was Foresite Capital Management III, cutting an estimated $22.7M.

  • 220 institutional investors held Immunomedics Inc (IMMU) as of Q1 2020, down from 245 in Q4 2019.
  • Funds reported $2.44B of Immunomedics Inc stock for Q1 2020, down 33% quarter-over-quarter.
  • 33 funds opened new Immunomedics Inc positions in Q1 2020 and 54 closed out, a net change of -21 holders.
  • The largest Immunomedics Inc buyer in Q1 2020 was Point72 Asset Management, an estimated $58.9M added.
  • The largest Immunomedics Inc seller in Q1 2020 was Foresite Capital Management III, an estimated $22.7M sold.

Based on aggregated 13F filings for Q1 2020.